Amendments to the Claims

Please cancel Claims 7 - 14, 19 - 30 and 33 - 52. Please amend Claims 1, 15, 31, 32, and 54 - 59. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A compound of Formula I,



(I);

or a physiologically acceptable salt thereof, wherein:

n is 0, 1 or 2;

X is O, CH_2, S or SO_2;

R_1 is H or NH_2;

R_2 and R_3 are each, independently, -H, -OH, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkoxy;

R_4 is, -H or a substituted or unsubstituted alkyl;

V is N or CH,

one of W and Z ~~are each, independently,~~ is N [[or]] and the other is CH; and

Y is selected from the group consisting of substituted and unsubstituted phenyl, substituted and unsubstituted heterocyclyl.

2. (Original) The compound of Claim 1, wherein Y is a phenyl group which has one or more substituents independently selected from the group consisting of halogen, linear or branched C_1-C_4-alkoxy, trifluoromethoxy, dioxymethylene, hydroxyalkyl, trifluoromethyl, HC(O)-, linear or branched C_1-C_4-alkyl, heterocyclyl and substituted or unsubstituted heterocycloalkylalkyl.

3. (Original) The compound of Claim 2, wherein Y is a phenyl group which has one or more substituents selected from the group consisting of fluoro, chloro, methoxy, morpholyl, N-morpholinomethyl, tetrahydroisoquinolyl, tetrahydroisoquinolinomethyl, 4-(4-benzyl-piperazin-1-yl)methyl, 4-(4-(2-fluoro-phenyl)piperazin-1-yl)methyl, and isopropyl.

4. (Original) The compound of Claim 1, wherein Y is selected from the group consisting of pyridyl, furyl, and pyrrolidyl.

5. (Original) A compound represented by the following structural formula:



;

or a physiologically acceptable salt thereof.

6. (Original) A compound represented by the following structural formula:



;

or a physiologically acceptable salt thereof.

7 - 14. (Cancelled)

15. (Currently Amended) A method of treating a TNF-α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula I,



(I);

or a physiologically acceptable salt thereof, wherein:

n is 0, 1 or 2;

X is O, CH_2, S or SO_2;

R_1 is H or NH_2;

R_2 and R_3 are each, independently, -H, -OH, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkoxy;

R_4 is, -H or a substituted or unsubstituted alkyl;

V is N or CH,

one of W and Z ~~are each, independently,~~ is N [[or]] and the other is CH; and

Y is selected from the group consisting of substituted and unsubstituted phenyl, and substituted and unsubstituted heterocyclyl,

wherein the condition is selected from the group consisting of rheumatoid arthritis, sepsis, inflammatory bowl disorder and multiple sclerosis.

16. (Original) The method of Claim 15, wherein Y is a phenyl group which has one or more substituents independently selected from the group consisting of halogen, linear or branched C_1-C_4-alkoxy, trifluoromethoxy, dioxymethylene, hydroxyalkyl, trifluoromethyl, HC(O)-, linear or branched C_1-C_4-alkyl, heterocyclyl and substituted or unsubstituted heterocycloalkylalkyl.

17. (Original) The method of Claim 16, wherein Y is a phenyl group which has one or more substituents selected from the group consisting of fluoro, chloro, methoxy, morpholyl, N-morpholinomethyl, tetrahydroisoquinolyl, tetrahydroisoquinolinomethyl, 4-(4-benzyl-piperazin-1-yl)methyl, 4-(4-(2-fluoro-phenyl)piperazin-1-yl)methyl, and isopropyl.

18. (Original) The method of Claim 15, wherein Y is selected from the group consisting of pyridyl, furyl, and pyrrolidyl.

19 - 30. (Cancelled)

31. (Currently amended) A method of treating a TNF-α mediated condition in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:



;

or a physiologically acceptable salt thereof,

wherein the condition is selected from the group consisting of rheumatoid arthritis, sepsis, inflammatory bowl disorder and multiple sclerosis.

32. (Currently amended) A method of treating a TNF-α mediated condition in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:



or a physiologically acceptable salt thereof,
wherein the condition is selected from the group consisting of rheumatoid arthritis, sepsis, inflammatory bowl disorder and multiple sclerosis.

33-52. (Cancelled)

53. (Original) A method of treating multiple sclerosis in a patient, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:



or a physiologically acceptable salt thereof.

54. (Currently Amended) A compound of Formula I,



(I);

or a physiologically acceptable salt thereof, wherein:

n is 0, 1 or 2;

X is O, CH_2, S or SO_2;

R_1 is H or NH_2;

R_2 and R_3 are each, independently, -H, -OH, a substituted or unsubstituted alkyl, or a substituted or unsubstituted alkoxy;

R_4 is, -H or a substituted or unsubstituted alkyl;

V is N or CH,

one of W and Z ~~are each, independently,~~ is N [[or]] and the other is CH; and

Y is represented by the following structural formula:



;

wherein R_{50} and R_{51} are independently an alkyl group, a substituted alkyl group, an aryl group a substituted aryl group, or, taken together with the nitrogen atom to which they are bonded, are a substituted heterocycloalkyl, an unsubstituted heterocycloalkyl, a substituted heteroaryl group or an unsubstituted heteroaryl. group.

55. (Currently amended) A method of treating a TNF-α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of the compound of Claim 54,

wherein the condition is selected from the group consisting of rheumatoid arthritis, sepsis, inflammatory bowl disorder and multiple sclerosis.

56. (Currently Amended) A compound represented by the following structural formula:



;

or a physiologically acceptable salt[[s]]thereof.

57. (Currently amended) A method of treating a TNF-α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of the compound of Claim 56,

wherein the condition is selected from the group consisting of rheumatoid arthritis, sepsis, inflammatory bowl disorder and multiple sclerosis.

58. (Currently Amended) A compound represented by the following structural formula:



;

or a physiologically acceptable salt[[s]] thereof.

59. (Currently amended) A method of treating a TNF-α mediated condition in a patient, comprising administering to the patient a therapeutically effective amount of the compound of Claim 58,

wherein the condition is selected from the group consisting of rheumatoid arthritis, sepsis, inflammatory bowl disorder and multiple sclerosis.